Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
70 results about "Neurite growth" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Factor
InactiveUS20070054961A1Administration of has been hamperedNeurite outgrowthBiocideNervous disorderAgonistNeurite growth
Owner:MADEN MALCOLM +1
4-substituted piperidine derivatives
ActiveUS7572913B2Promote neurite outgrowthPotential curative effectAntibacterial agentsBiocideDiseaseCell membrane
Substituted piperidine compounds represented by the structure I are provided,wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
Owner:BIOAXONE BIOSCI
4-Substituted piperidine derivatives
ActiveUS20050272751A1Promote neurite outgrowthPotential curative effectAntibacterial agentsBiocideDiseaseNervous system
Substituted piperidine compounds represented by the structure I are provided, wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
Owner:BIOAXONE BIOSCI
Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
Owner:TRIAD
Pramyxovirusl vectors encoding antibody and utilization thereof
InactiveUS20050191617A1Good effectImprove efficiencySsRNA viruses negative-senseNervous disorderSingle-Chain AntibodiesAntibody fragments
The present invention provides paramyxoviral vectors expressing polypeptides that comprise antibody variable regions. A vector of this invention, encoding antibody variable regions of the H and L chains, succeeded in simultaneously expressing these antibody chains to form a Fab, and further succeeded in expressing a single chain antibody at a high level. The vectors of this invention are suitable as vectors for gene therapy, to be administered in vivo or ex vivo to living bodies. In particular, vectors expressing antibody fragments against neurite outgrowth inhibitors are useful in gene therapies for nerve lesions. Further, vectors of this invention that express antibodies which inhibit immune activation signal transduction enable the long-term expression of genes from the vectors.
Owner:DNAVEC RES
Treatment of CNS tumors with metalloprotease inhibitors
InactiveUS6025333AAvoid environmentIncrease the areaOrganic active ingredientsNervous disorderAbnormal tissue growthNervous system
The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system. The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.
Owner:ZURICH UNIV OF
Peptide amphiphiles and methods to electrostatically control bioactivity of the ikvav peptide epitope
ActiveUS20120294902A1Superior solubility and biological activityEnhances displayConnective tissue peptidesNervous disorderChemistrySolubility
The present invention is directed to peptide amphiphile compounds, compositions and methods of use, wherein nanofiber bundling or epitope aggregation is inhibited. In certain embodiments, the peptide amphiphiles of the present invention have increased solubility and reduced nanofiber bundling. The molecules may be used in pharmaceutical applications, for example for in vivo administration to human patients, by increasing biological activity of the compositions toward neurite outgrowth and nerve regeneration.
Owner:NORTHWESTERN UNIV
Molecules for targeting compounds to various selected organs, tissues or tumor cells
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat neuronal or neuromuscular disease, or a pathology of the brain, or a tumor of neuronal or neuroectodermal origin, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the brain cells or neuronal cells, or by the tumor cells of neuronal or neuroectodermal origin. The invention also provides a method of identifying and measuring neurite growth in neuronal cells.
Owner:BIOMARIN TECH BV
Design of a conduit for peripheral nerve replacement
A biphasic material and devices comprising the same are provided for the development of conductive conduits that may be used for the treatment of peripheral nerve injury. These devices or conduits are designed such that repeated electric field gradients can be initiated to promote neurite and axonal outgrowth. Conducting conduits using doped synthetic and / or natural polymers create specifically patterned high and low conducting segmented materials, which are mechanically used to produce the electrical properties needed for nerve conduits. These electrical properties stimulate neurite outgrowth and axonal repair following a peripheral nerve transection.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Neuron generation, regeneration and protection
ActiveUS20120100116A1Positive neurite outgrowth effectGood effectOrganic active ingredientsVirusesNervous systemNeoplasm
The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and / or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
Owner:INST PASTEUR +1
Molecules for targeting compounds to various selected organs, tissues or tumor cells
InactiveUS20100184947A1Improving in vivo uptakeNervous disorderIn-vivo radioactive preparationsDiseaseGerm layer
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat neuronal or neuromuscular disease, or a pathology of the brain, or a tumor of neuronal or neuroectodermal origin, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the brain cells or neuronal cells, or by the tumor cells of neuronal or neuroectodermal origin. The invention also provides a method of identifying and measuring neurite growth in neuronal cells.
Owner:BIOMARIN TECH BV
Cyclohexenone long-chain alcohol and medicament containing same
InactiveUS6228893B1Excellent neurite growth promoting effectPromote neurite growthBiocideNervous disorderDiseaseCyclohexanone
Described is a cyclohexenone long-chain alcohol represented by the formula (1):wherein R1, R2 and R3 each independently represents a hydrogen atom or a methyl group and X represents a C10-18 alkylene or alkenylene group. The cyclohexanone long-chain alcohol according to the present invention has excellent neurite growth stimulating effects and is therefore useful as a preventive and / or therapeutic agent for Alzheimer's disease.
Owner:CENT NAT DE LA RECHERCHE SCI +1
Biologically active peptides as glutamate receptor inhibitors
The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of luminin-1, i.e. the γ1-chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI (SEQ ID NO: 1) and the truncated peptides derived therefrom comprising the biologically active domain thereof, the tripeptide KDI. The invention is directed to the biologically active tripeptide motifKDI, and to its use in promoting regeneration of neuronal or non-neuronal tissues and, in specific, to its use in the treatment of spinal cord injuries.
Owner:LIESI PAIVI
Neurite growth regulatory factors
InactiveUS6103232AAvoid environmentIncrease the areaNervous disorderHydrolasesNerve fiber bundleMyelin
The present invention relates to methods of inducing neurite outgrowth in the central nervous system by antagonizing neural growth inhibitory factors. More particularly, the present invention is directed to use of antibodies to the central nervous system (CNS) myelin associated proteins; such antibodies can be used in the diagnosis and therapies of nerve damage resulting from trauma, infarction, and degenerative disorders of the CNS. In a specific embodiment of the invention, the monoclonal antibody IN-1 may be used to promote neurite outgrowth of nerve fibers over long distances in spinal cord lesions.
Owner:ZURICH UNIV OF
Agents, compositions and methods for enhancing neurological function
InactiveUS20100204192A1Improve and restore neurological functionMaximizes neurogenesisOrganic active ingredientsNervous disorderProgenitorDisease
Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and / or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.
Owner:UNIV OF SOUTHERN CALIFORNIA
Compounds that modulate neuronal growth and their uses
InactiveUS20050164920A1Enhancing Trk mediated activityEnhances Trk mediated activityNervous disorderDepsipeptidesCyclic peptideNervous system
Cyclic peptides and peptidomimetics are provided that bind to and / or modulate activities associated with Trk receptors, including processes associated with the growth and repair of the central nervous system (e.g., neuronal growth and survival, axonal growth, neurite outgrowth and synaptic plasticity). Cyclic peptides and peptidomimetics are also provided that block or reduce the effect of other factors that inhibit growth and / or repair of the central nervous system. Pharmaceutical compositions and other formulations comprising these compounds are provided. In addition, the invention provides methods for using the cyclic peptides and peptidomimetics to modulate Trk mediated activities, including processes such as neuronal growth, survival and recover, axonal growth, neurite outgrowth, and synaptic plasticity. Further, the invention provides methods for promoting central nervous system (CNS) neuron growth by administering a p75 receptor binding agent.
Owner:WYETH LLC +1
Allopregnanolone in a method for enhancing neurological function
ActiveUS8969329B2Improve neurological functionReduce accumulationOrganic active ingredientsNervous disorderProgenitorDisease
Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and / or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.
Owner:UNIV OF SOUTHERN CALIFORNIA
Administration of HB-EGF for the Protection of Enteric Neurons
InactiveUS20120053121A1Alleviate intestinal dysmotilityImpaired intestinal motilityNervous disorderPeptide/protein ingredientsNervous systemHEPARIN-BINDING EGF
The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.
Owner:NATIONWIDE CHILDRENS HOSPITAL
Preparation method and applications of ganglioside derivatives containing unsaturated fatty acid chains
ActiveCN108498523AHigh synthetic activityLow hydrolytic activityOrganic active ingredientsNervous disorderCarbon chainGangliosidosis
The present invention relates to applications of a group of ganglioside derivatives containing unsaturated fatty acid chains in promotion of neurite growth. According to the present invention, the library of ganglioside derivatives containing unsaturated fatty acid chains is synthesized through a sphingolipid ceramide N-deacylase method, and is combined with the classical neurite growth promotioncell model; and the results show that the ganglioside derivatives containing unsaturated fatty acid chains have the significantly-improved biological activity of the neurite growth promotion, and thedifferent number of the carbon chains of the ganglioside sphingosine base can significantly affect the biological activity of the neurite growth promotion.
Owner:SHANGHAI JIAO TONG UNIV
1,4-Substituted cyclohexane derivatives
InactiveUS20040138272A1Inhibit cell proliferationInhibit apoptosisAntibacterial agentsBiocideDiseaseNervous system
Allylic compounds represented by the formula (I) are provided, wherein each of R1 to R8, m, n, A and X are as defined in the Specification. These compounds can inhibit Rho kinase, and can find utility in repair of damaged nerves in the central and peripheral nervous system by inducing axon growth and regeneration, and in the treatment by inhibition of Rho kinase in disease states in which Rho kinase is implicated. The compounds are relatively cell permeable and pharmaceutical compositions thereof can promote neurite growth and are also useful for the prevention of cell proliferation in malignant deseases.
Owner:UNIV DE MONTREAL
Device for axon and neurite growth and method for producing the same
InactiveUS20060251698A1Direction is limitedPromote growthNervous system cellsCell culture supports/coatingMicrocontact printingNeuron
The present invention relates to a device for directing and accelerating the growth of neuronal axon or neurite. The invention accelerates the growth speed of axon of nerve cells by using a substrate configured with a discontinuous micropattern of neuronal path-finding molecules or material thereon. The invention can reduce the connection or regeneration time of neural network. The present invention also discloses a micro-contact printing method for producing the device.
Owner:IND TECH RES INST
Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARβ2), to cause or promote neurite development, neurite outgrowth, and / or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.
Owner:KING'S COLLEGE LONDON
Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
Owner:KINGS COLLEGE LONDON
Compositions for inducing cell growth and differentiation and methods of using same
InactiveUS20050153887A1Peptide/protein ingredientsGenetic material ingredientsNeuronal diseaseCell growth
Compositions, including, for example, soluble Ryk polypeptides and Wnt polypeptides, that induce cell growth and / or differentiation, including, for example, neurite outgrowth and hematopoietic cell proliferation and differentiation, are provided. Methods of using such compositions also are provided, including, for example, methods of using such compositions to induce neurite outgrowth (e.g., in a subject having a neuronal disorder). In addition, methods to identify agents that alter Ryk mediated signal transduction in a cell are provided.
Owner:CALIFORNIA INST OF TECH
Methods of treatment
InactiveUS20100092456A1Inhibit apoptosisLower Level RequirementsOrganic active ingredientsNervous disorderDiseaseApoptosis
Methods for modulating apoptosis and neurite outgrowth in cells by modulating levels of PtdIns(4,5)P2. Agents for such modulation, including agents which inhibit or activate type I and type II PIP kinases, and methods for identifying such agents. Methods for treating or preventing hyperproliferative disorders and neurodegenerative diseases using such agents.
Owner:BISSET LOUISE +3
Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
ActiveUS20100105646A1Improve neurological functionPrevent neuronal lossOrganic active ingredientsNervous disorderProgenitorMetabolite
Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and / or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.
Owner:UNIV OF SOUTHERN CALIFORNIA
Novel polysaccharides and oligosaccharides
InactiveUS20070232565A1Useful applicationBiocideOrganic active ingredientsDiseaseChondroitin Sulfate C
Polysaccharides and oligosaccharides having activity of binding to different proliferation factors and neurite outgrowth-promoting activity and compositions for neurological disease treatment, compositions for inflammatory disease treatment, or compositions for wound treatment, which comprise such polysaccharides and oligosaccharides, are provided. Chondroitin sulfate / dermatan sulfate hybrid chains, chondroitin sulfate C, and oligosaccharides derived from either thereof are provided.
Owner:KAZUYUKI SUGAHARA +1
Identification of novel nogo-receptors and methods related thereto
InactiveUS20070032406A1Organic active ingredientsCell receptors/surface-antigens/surface-determinantsDiseaseAntibody fragments
Disclosed are compositions relating to the Nogo receptor (NgR) family as well as fragments, chimeras, and variants thereof. The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the NgRs as well as uses thereof. Such uses include modulation neurite outgrowth in a subject and treatment of central nervous system disorders in a subject, as well as, methods of identifying and screening compounds that can be used for modulating neurite outgrowth in a subject or in treatment of central nervous system disorders in a subject.
Owner:UNIVERSITY OF ROCHESTER
Local cochlear application of statins for stimulating neurite regrowth in the cochlea
Statin compositions are disclosed for stimulating neurite growth from spiral ganglion neurons in the inner ear and methods for preventing damage to or treating damage of auditory neurons and / or hair cells of the cochlea following acoustic or toxic insult.
Owner:NORTHWESTERN UNIV
Composite nerve conduit and preparation method thereof
ActiveCN107343969AImprove mechanical propertiesStable microenvironmentProsthesisNanofiberNerve cells
The invention discloses a composite nerve conduit and a preparation method thereof. The method comprises the following steps of (1) preparing an outer-layer conduit; (2) preparing an inner-layer nanofiber membrane; (3) under the action of an initiator, reacting the inner-layer nanofiber membrane prepared through the step (2) with a polypeptide growth factor, and thus obtaining an inner-layer nanofiber membrane loaded with the polypeptide growth factor; (4) installing the inner-layer nanofiber membrane loaded with the polypeptide growth factor prepared through the step (3) in the outer-layer conduit in the step (1) in a casing way, and thus obtaining the composite nerve conduit. In the composite nerve conduit, the outer-layer conduit has an excellent mechanical property, and can provide a stable microenvironment for growth and proliferation of internal nerve cells. The inner-layer nanofiber membrane provides a physical support for the attachment of the nerve cells, and the polypeptide growth factor loading on the inner-layer nanofiber membrane can simulate a development and growth environment of the nerve cells, so that a biochemistry clue is provided for neurite growth.
Owner:北京智枢生物科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com